The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate

• Published in: PloS one Vol. 17; no. 2; p. e0263684
• Main Authors: Jung, Bo-Kyoung, An, Yong Hee, Jang, Jin-Ju, Jeon, Joo Hee, Jang, Sung Hoon, Jang, Hyun
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 08.02.2022; Public Library of Science (PLoS)
• Subjects: ACE inhibitors; Analysis; Angiotensin-Converting Enzyme 2 - immunology; Animals; Antibodies; Antibodies, Neutralizing - immunology; Antibodies, Viral - immunology; Antigens; Binding; Biology and life sciences; Coronaviruses; COVID-19; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 - virology; COVID-19 vaccines; COVID-19 Vaccines - immunology; Diagnosis; Disease transmission; Domains; Economic impact; Fatalities; Female; Gene expression; Genetic aspects; Genomes; Humans; Impact analysis; Infections; Medicine and health sciences; Mice; Mice, Inbred BALB C; Neutralization; Newcastle disease; Newcastle disease virus - genetics; Newcastle disease virus - immunology; Optical density; Pandemics; Patients; Peptides; Pneumonia; Protein Binding; Protein Domains; Protein folding; Proteins; R&D; Receptors; Research & development; Research and Analysis Methods; SARS-CoV-2 - immunology; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Vaccines; Vectors (Biology); Viral diseases; Viral infections; Viral Vaccines - immunology; Viruses; South Korea; Europe; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0263684

Since the SARS-CoV-2 infection was identified in December 2019, SARS-CoV-2 infection has rapidly spread worldwide and has become a significant pandemic disease. In addition, human death and serious health problem caused by SARS-CoV-2 infection, the socio-economic impact has been very serious. Here, we describe the development of the viral vector vaccine, which is the receptor-binding domain (RBD) of SARS-CoV-2 expressed on the surface of Newcastle disease virus (LVP-K1-RBD19). The RBD protein concentrations on the viral surface were measured by the sandwich ELISA method. 10 6.7 TCID 50 /ml of LVP-K1-RBD19 has a 0.17 μg of RBD protein. Optical density (OD) values of mouse sera inoculated with 10 μg of RBD protein expressed on the surface of LVP-K1-RBD19 generated 1.78-fold higher RBD-specific antibody titers than mice inoculated with 10 μg RBD protein with alum at 28 dpi. Moreover, mice inoculated with 10 μg of RBD protein expressed on the surface of LVP-K1-RBD19 virus showed more than 80% neutralization at 1:256 against the SARS-CoV-2 pseudovirus. These results demonstrated that inactivated LVP-K1-RBD19 virus produces neutralizing antibodies against SARS-CoV-2 in a short period and could be elect protective immunity in humans and LVP-K1-RBD19 will be a good candidate for the COVID-19 vaccine.